NEWS: Ketchum to handle new anti-depressant launch

Ketchum Public Relations is to co-ordinate communications for the global launch of anti-depressant prescription drug Remeron.

Ketchum Public Relations is to co-ordinate communications for the global

launch of anti-depressant prescription drug Remeron.



Remeron’s manufacturers Organon signed up Ketchum PR’s healthcare

division two weeks ago after seeing it pitch against healthcare

specialist Shire Hall Communications.



The campaign, which is believed to be worth an estimated pounds 150,000

in fees, will target psychiatrists and GPs throughout the world. The

launch will kick off in the Netherlands and Finland.



The agency is planning to liaise with local agencies in each country,

reaching potential audiences through a combination of specialist media

and professional relations activities.



Remeron is a hybrid of the two existing classes of anti-depressant

medicines; the strong tri-cyclic drugs which are prone to side-effects

and the milder division of Selective Seratonin Re-uptake Inhibitors

(SSRIs).



‘We will work closely with experts to ensure psychiatrists and GP’s

understand the difference with the new class,’ said Paul Blackburn,

director of Ketchum PR’s healthcare arm. ‘Remeron is potent, but it has

minimal side effects,’ he added.



Other clients handled by Ketchum’s five-strong healthcare division

include Abbott Laboratories and Rhone Poulenc-Rorer.



Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.